Thymalin

What it is

The story begins in the Cold War in Leningrad. The military physician Vladimir Khavinson was tasked with finding ways for soldiers to recover faster after radiation exposure, poisoning or exhaustion. His idea: every organ has its own short peptides that control gene activity in the cells of exactly that tissue. Khavinson called them bioregulators. When an organ ages and these signals weaken, they are supposed to be resupplied from outside, as an extract from calf organs or rebuilt synthetically.

Thymalin was the first preparation of this technology, a polypeptide complex from the thymus of young calves, described in the early 1980s and, according to the developers, approved as a medicine in the Soviet Union and later in Russia since 1982. The developer group has isolated several active short peptides from it: the dipeptide Glu-Trp, which is marketed synthetically as Thymogen, the dipeptide Lys-Glu and the tripeptide Glu-Asp-Pro. In the Khavinson system, Thymalin, alongside Epitalon for the pineal gland, is one of the most important regulators, because the immune system and hormonal control are considered the two main systems of aging.

Why the thymus matters in aging

The thymus sits behind the breastbone and is the training ground of your immune defense: this is where the T cells mature, the virus killers and conductors of the immune system. From puberty onward the organ begins to shrink and, over the decades, turns almost completely into fat. Experts call this thymic involution. The consequence is immunosenescence: older immune systems respond more slowly to new pathogens, vaccinations work less well, and infections become more dangerous.

In parallel runs so-called inflammaging, a chronic, low-grade inflammation that strains blood vessels, joints and the brain. The idea of strengthening the thymus again in old age has long since reached the Western mainstream as well. The Californian TRIIM study attempted this in men between 51 and 65 years with growth hormone, DHEA and metformin and reported an epigenetic age about 1.5 years lower on average after one year. Thymalin itself was not part of that study, but the basic idea is the same.

How it is supposed to work

According to the developer group’s data, Thymalin acts on two levels. Directly, it promotes the maturation and balance of T cells; the ratio of helper to suppressor cells is said to normalize, and antibody formation and phagocyte activity are said to increase. In a cell culture study with human blood-forming stem cells, Thymalin increased the marker of mature T cells CD28 6.8-fold and lowered stem cell markers 2- to 3-fold, an indirect indication of maturation toward the T cell.

The second level is conceived as epigenetic: the short peptides are said to bind to DNA and histones and switch genes for immune messengers and cell protection on or off there. This is the core thesis of the Khavinson school, but it rests mainly on cell culture and computer models from the same group.

Use and reports

In Russia, Thymalin is given as an injection in short courses, following the bioregulator principle: give a brief push, then let it work. In the scene, subcutaneous variants and alternating use with Epitalon also circulate. For anyone who dislikes injections, there are oral short-peptide capsules from the Khavinson school; the thymus representative is called Vladonix, and the data on it are thinner than for the injection. We give no dosage, because Thymalin is not approved in the EU.

Reports of good tolerability, fewer infections and more energy are plentiful. However, they come almost entirely from the vendors’ circle and from publications of the developer group. That does not make them wrong, but they lack the independence that otherwise makes user reports strong. And there are things anyone can do for their thymus without a peptide: ensure adequate zinc and protein, train regularly and reduce chronic stress.

What the studies show

Khavinson & Morozov 2003 — mortality over 6 to 8 years

266 older people received Thymalin, Epithalamin, both or nothing, and only in the first 2 to 3 years of observation. Compared with the control group, mortality fell 2.0- to 2.1-fold under Thymalin, 1.6- to 1.8-fold under Epithalamin and 2.5-fold under the combination. A separate group that received both peptides annually over 6 years had 4.1 times lower mortality. How the groups were formed, whether there was blinding and how large the individual groups were is not described in the abstract.

Kuznik et al. 2021 — severe COVID-19 in older people

Prospective, randomized and single-blind, 36 patients with Thymalin plus standard therapy versus 44 with standard therapy alone, with Khavinson as co-author. The proportion with clinical improvement was 80.5 versus 59 percent, thus meeting the study goal, whereas the time to improvement and the CT findings on day 14 did not differ. In-hospital mortality, a secondary endpoint, was 19.4 versus 40.9 percent. In the control group, however, more patients were invasively ventilated, 45.4 versus 25 percent.

Khavinson et al. 2020 — stem cells in a culture dish

Despite the title about human stem cells, this is purely a cell culture study. Thymalin lowered the stem cell markers CD44 and CD117 2- to 3-fold and increased the T cell marker CD28 6.8-fold. This supports the idea of promoted T cell maturation, but is not evidence of an effect in the body.

Where the data stop

The central problem is the source. Practically all clinical data come from the research group around Khavinson or have him as a co-author, and appeared mostly in Russian or small journals. No independent replication outside Russia was found. In the 2003 long-term study, randomization, blinding, group sizes and the recording of deaths are not described in a traceable way, and for a claim as strong as halved mortality that is too little.

The often-cited fourfold lower mortality with Epitalon is also reported inaccurately: the combination group was at 2.5-fold, and the figure of 4.1-fold applies only to a separate group with annual treatment over 6 years. The COVID study is small, only single-blind, mortality was a secondary endpoint, and the groups were unevenly distributed with regard to ventilation. For the oral variant Vladonix there are even fewer data.

Status, approval and legal

According to the developers, Thymalin has been approved as a medicine in the Soviet Union and Russia since 1982 and was used there again during the pandemic as an adjunct therapy. In the EU and in Germany it is not approved; it is obtained as a research peptide via the gray market, and purity and content are up to the vendor. Thymalin is not listed by name on the 2026 WADA prohibited list, which lists only thymosin β4; a reliable classification by an anti-doping body could not be found. We do not give dosage information for unapproved active substances.

Safety

In the Russian clinical literature, Thymalin is considered very well tolerated; the developer group speaks of practically no side effects. Reported are mainly reactions at the injection site and, rarely, allergic reactions. Systematic safety data by Western standards do not exist. Caution applies in autoimmune diseases, because an immune stimulant could theoretically also fuel the wrong side, and after organ transplantation; both belong in the hands of a physician. There are no data for pregnant women. With an extract from animal tissue, much depends on manufacturing quality; without a certificate of analysis, gray-market products cannot be assessed.

Sources

• Khavinson & Morozov, Neuro Endocrinology Letters 2003
• Khavinson et al., Biology Bulletin Reviews 2021
• Kuznik et al., Advances in Gerontology 2021
• Khavinson et al., Bulletin of Experimental Biology and Medicine 2020
• Fahy et al., Aging Cell 2019 (TRIIM)
• WADA, Prohibited List 2026